Key facts
- It has raised $1.5M; the latest was Early Stage VC ($1.5M) in Feb 2026.
- Notable investors include Hard2beat, Jagiellonian University.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Melanos Care
- ·The full record, as it builds
Funding rounds
No funding rounds for Melanos Care are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Melanos Care
Developer of bio-identical melanin and cinnamic acid derivatives designed to revolutionize photoprotection and hyperpigmentation treatment through regenerative biotechnology. The company offers iPSC-derived biologics and proprietary active ingredients that utilize stem cell technology to create bio-identical human melanin, enabling clients to offer long-lasting UV protection and superior depigmentation efficacy that outperforms current global standards.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Kraków, Poland
- Founded
- 2023
- Website
- melanoscare.com/
- Ownership
- Privately Held (backing)
Melanos Care doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Melanos Care shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Melanos Care in its N-PORT filings yet. We sweep new filings monthly.